RefleXion’s SCINTIX BgRT Achieves 100% Local Disease Control in Lung and Bone Metastases
RefleXion Medical’s SCINTIX biology-guided radiotherapy (BgRT) demonstrated 100% local disease control in patients with lung and bone metastases in a US observational study (PREMIER trial, NCT05406167). At nine-month follow-up, 41% of patients achieved complete or partial responses, including 47% with bone metastases and 35% with lung tumors.
The treatment was well-tolerated, with no adverse events above Grade 2 reported. SCINTIX combines PET imaging with a linear accelerator, enabling precision radiation dosing while sparing healthy tissue, and represents a first-in-class theranostic radiotherapy system.
CMS reimbursement and FDA approval further support its clinical adoption, with expanded registry enrollment planned to assess long-term outcomes.
01-10-2025
📰 Recent News
- EG 427’s EG110A Gene Therapy Shows >80% Reduction in Urinary Incontinence Episodes in NDO Patients
- RefleXion’s SCINTIX BgRT Achieves 100% Local Disease Control in Lung and Bone Metastases
- SCYNEXIS Reports Positive Phase I Results for Oral SCY-247
- MSD’s Winrevair Significantly Reduces Clinical Worsening in Early PAH
- Enanta Pharmaceuticals’ RSV Trial Misses Primary Endpoint but Stock Surges
- MBX Biosciences’ Canvuparatide Shows Promising Phase II Results in Hypoparathyroidism
- Neurocrine’s Osavampator Shows Strong Efficacy and Safety in Phase II MDD Trial
- Sensory Cloud’s SC0023 Shows Promise in Refractory Chronic Cough Phase II Trial
- BMS Iberdomide Shows Promising MRD Results in Phase III Multiple Myeloma Trial
- Harmony Biosciences’ Cannabidiol Therapy Misses Phase III Endpoint in Fragile X Syndrome